A breast cancer specialist and clinical researcher shows that adding either the chemotherapy drug carboplatin or the blood vessel-targeting drug bevacizumab to the standard treatment of chemotherapy before surgery helped women who have the basal-like subtype of triple-negative breast cancer.
from Today's Healthcare News -- ScienceDaily http://ift.tt/1uLFK0R
from Today's Healthcare News -- ScienceDaily http://ift.tt/1uLFK0R
No comments:
Post a Comment